HAYWARD, Calif., April 19, 2012 /PRNewswire/ -- Solta
Medical, Inc. (Nasdaq: SLTM), the pioneer in fractional resurfacing
and a global market leader in aesthetic treatments, today announced
the results of a first-of-its-kind, IRB-approved clinical study
that evaluated the use of its novel 1440nm fractional laser to
assess the effect of this treatment on the appearance of pores,
skin texture and overall appearance of skin. The study utilized
Solta's newest fractional resurfacing platform, the Clear +
Brilliant™ Laser System, which is used by clinicians worldwide
to help patients prevent the initial signs of photo-aging, maintain
the look and feel of their youthful appearance, and improve the
texture and tone of aging and sun-damaged skin. The complete
research findings will be presented at the 32nd American Society
for Laser Medicine and Surgery (ASLMS) Annual Conference in
Kissimmee, Fla. on April 18 through April 22, 2012.
The clinical study is the first to objectively measure the
effects of a fractional device on facial pores. It included 20
patients (Fitzpatrick I-IV) who received six treatments spaced two
weeks apart. Each patient received a full-face treatment consisting
of eight passes at the highest tolerable energy level. A
photographic assessment of facial pores using the VISIA-CR Imaging
system was performed before treatment at each visit and subjective
measurements were recorded by both the subject and investigator
regarding pore appearance, appearance of skin texture, and overall
skin appearance. After a series of six treatments, there was a
significant reduction in pore score (p